Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumeq in ALS (Lighthouse III)
NCT06658977Phase 3Terminated
- Sponsor
- Macquarie University
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abacavir in amyotrophic lateral sclerosis (ALS), sponsored by Macquarie University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Nov 2024; status: terminated.
02
Drugs
abacavir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06658977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658977.